List of Advair Hfa drug patents

Advair Hfa is owned by Glaxo Grp Ltd.

Advair Hfa contains Fluticasone Propionate; Salmeterol Xinafoate.

Advair Hfa has a total of 4 drug patents out of which 0 drug patents have expired.

Advair Hfa was authorised for market use on 08 June, 2006.

Advair Hfa is available in aerosol, metered;inhalation dosage forms.

The generics of Advair Hfa are possible to be released after 26 August, 2026.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7832351 GLAXO GRP LTD Actuation indicator for a dispensing device
Jun, 2023

(4 months from now)

US7832351

(Pediatric)

GLAXO GRP LTD Actuation indicator for a dispensing device
Dec, 2023

(10 months from now)

US7500444 GLAXO GRP LTD Actuation indicator for a dispensing device
Feb, 2026

(3 years from now)

US7500444

(Pediatric)

GLAXO GRP LTD Actuation indicator for a dispensing device
Aug, 2026

(3 years from now)

Drugs and Companies using FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE ingredient

Market Authorisation Date: 08 June, 2006

Treatment: NA

Dosage: AEROSOL, METERED;INHALATION

More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic